The Next-Gen GLP-1 Hits 16% Weight Loss. What to Eat
A phase 3 trial of survodutide, a dual GLP-1 plus glucagon drug, reported 16.6% weight loss over 76 weeks. As appetite suppression gets stronger, the food side gets harder, not easier.
7 articles
A phase 3 trial of survodutide, a dual GLP-1 plus glucagon drug, reported 16.6% weight loss over 76 weeks. As appetite suppression gets stronger, the food side gets harder, not easier.
New BMJ research tested whether sparkling water speeds metabolism enough to drive weight loss. The honest answer deflates a lot of viral TikTok claims.
A Stanford and ETH Zurich study found about 10% of people carry PAM gene variants linked to GLP-1 resistance, which may reduce how effectively Ozempic lowers blood sugar.
A tiny 12-amino-acid peptide called BRP may curb appetite like semaglutide, without the nausea or muscle loss. Stanford researchers used AI to find it.
Research shows your food environment shapes your diet more than discipline. Two viral Reddit threads and decades of data agree: where you eat determines what you eat.
A Bristol study found people eat 57% more food on whole diets but 330 fewer calories. Your body has nutritional intelligence — here is how it works.
A 2026 Cochrane review questions intermittent fasting claims. Here's what the evidence actually says about IF and weight loss.